


## The Oxidation of 5-Methyl-<sup>14</sup>C-tetrahydrofolate and Histidine-2-<sup>14</sup>C to <sup>14</sup>CO<sub>2</sub> in Vitamin B<sub>12</sub>-Deficient Rats<sup>1</sup> (34759)

S. W. THENEN,<sup>2</sup> J. M. GAWTHORNE,<sup>3</sup> AND E. L. R. STOKSTAD

Department of Nutritional Sciences, University of California, Berkeley, California 94720

Evidence for a metabolic interrelationship between vitamin B<sub>12</sub> and folic acid is abundant. The macrocytic, megaloblastic anemia seen in humans is caused by a deficiency of either vitamin (1), as is the elevated urinary excretion of formiminoglutamic acid (FIGlu)<sup>4</sup> in humans, rats and chicks (2-6). The essential amino acid methionine is involved in the interrelationship since its presence in adequate or excess amounts can restore to normal the high urinary FIGlu excretion in rats (3, 7) and humans (8). The only known metabolic pathway common to folic acid, vitamin B<sub>12</sub>, and methionine includes the 5-methyltetrahydrofolate: L-homocysteine S-methyltransferase reaction shown in the following scheme:



5-Methyl-H<sub>4</sub>PteGlu is formed from 5,10-methylene-H<sub>4</sub>PteGlu by a reductase enzyme

<sup>1</sup> Supported in part by NIH Grant No. AM 08171.

<sup>2</sup> Present address: Hematology Research Laboratory, Harvard Medical School, Massachusetts General Hospital, Boston, Mass.

<sup>3</sup> CSIRO Postdoctoral Fellow. Present address: Division of Nutritional Biochemistry, CSIRO, Kintore Ave., Adelaide, South Australia.

<sup>4</sup> Abbreviations: FIGlu, formiminoglutamic acid; H<sub>4</sub>PteGlu, tetrahydrofolic acid; 5-CH<sub>3</sub>-H<sub>4</sub>PteGlu, 5-methyltetrahydrofolic acid; SAM, S-adenosylmethionine; FADH<sub>2</sub>, flavin-adenine dinucleotide (reduced).

requiring FADH<sub>2</sub>, and the 5-methyl-H<sub>4</sub>PteGlu donates its methyl group to homocysteine to form methionine and H<sub>4</sub>PteGlu. This methyltransferase reaction requires vitamin B<sub>12</sub> and S-adenosylmethionine as cofactors in mammalian systems. The released H<sub>4</sub>PteGlu can be utilized by the formiminotransferase enzyme to accept the formimino group from FIGlu with the formation of 5-formimino-H<sub>4</sub>PteGlu and glutamic acid.

Several investigators have discussed the possibility that a metabolic deficiency of folic acid exists in vitamin B<sub>12</sub> deficiency as a consequence of impairment in the vitamin B<sub>12</sub>-dependent methyltransferase reaction. *In vitro* evidence shows that methylenetetrahydrofolate reductase is essentially irrevers-

ible (9, 10), and it is therefore contended that accumulation or "trapping" of metabolically active folates such as 5-CH<sub>3</sub>-H<sub>4</sub>PteGlu occurs (11-14). If these current concepts are correct, changes in the rate of catabolism of compounds such as histidine, that require H<sub>4</sub>PteGlu for one-carbon transfer, will follow changes in the rate of the methyltransferase reaction.

In order to examine this prediction we have compared the <sup>14</sup>CO<sub>2</sub> production from histidine (imidazole-2-<sup>14</sup>C) with that from 5-<sup>14</sup>CH<sub>3</sub>-

H<sub>4</sub>PteGlu in rats fed diets differing in vitamin B<sub>12</sub> and methionine content, and thus likely to cause changes in the rate of the methyltransferase reaction.

**Materials and Methods. Diets.** The basal diet had the following composition (g/kg): soy assay protein,<sup>5</sup> 200; glucose monohydrate, 714; corn oil with vitamins A, D and E, 40; salt mix (15), 35; vitamin premix in glucose monohydrate, 10; choline chloride, 1. The vitamins were supplied in the following amounts (per kg): vitamin A, 15,000 IU; vitamin D (viosterol), 2000 units;  $\alpha$ -tocopherol acetate, 50 mg; biotin, 0.2 mg; thiamine·HCl, 15 mg; riboflavin, 15 mg; pyridoxine·HCl, 15 mg; Ca-pantothenate, 50 mg; niacin·HCl, 50 mg; menadione, 10 mg; folic acid, 5 mg. When the basal diet was supplemented with vitamin B<sub>12</sub> and/or D,L-methionine, the levels were 100  $\mu$ g/kg and 3 g/kg, respectively.

**Animals.** Male, weanling rats of the Sprague-Dawley strain<sup>6</sup> were housed singly in stainless steel screen-bottom metabolism cages in a constant temperature and light-controlled room. Four animals were assigned to each of the 4 diet groups described in Table I and fed the diets and water *ad libitum* for 8 weeks before commencing the metabolic tests.

**Methylmalonic acid determination.** A 24-hr urine collection was made from each rat after 8 weeks on the diets and methylmalonic acid analysis was performed as evidence of vitamin B<sub>12</sub> deficiency. The method of Giorgio and Plaut (16) was used with an adaptation for automated analysis. One- to 2-ml urine samples were passed through 3  $\times$  1.3-cm columns of Bio-Rex 5<sup>7</sup> anion exchange resin, 100–200 mesh. The methylmalonic acid was eluted with 25 ml of 0.2 N HCl and assayed directly with an autoanalyzer using diazotized *p*-nitroaniline reagent for the color reaction.

**<sup>14</sup>CO<sub>2</sub> studies.** The radioactive compounds

<sup>5</sup> Obtained from General Biochemicals, Chagrin Falls, Ohio; Contains 1.0% methionine.

<sup>6</sup> Simonson Laboratories, Gilroy, Calif.

<sup>7</sup> Obtained from Bio-Rad Laboratories, Richmond, Calif.

administered were L-histidine (imidazole-2-<sup>14</sup>C), 57.8 mCi/mmol and 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu (barium salt), 50.8 mCi/mmol.<sup>8</sup> Continuous tracings of pulmonary <sup>14</sup>CO<sub>2</sub> were recorded using a technique developed by Tolbert *et al.* (17). Each animal was placed in a glass metabolism chamber after injection of the radioactive compound and the expired air was measured for radioactivity using a flow system ionization chamber with a vibrating reed electrometer<sup>9</sup> and a strip chart recorder.<sup>10</sup> The total CO<sub>2</sub> was collected for a 60-min period using an ethanolamine–ethylene glycol monomethyl ether trapping solution and then counted for radioactivity with a scintillation counter (18).

On day 1 of the CO<sub>2</sub> collection study, each rat was injected in the femoral vein with 2  $\mu$ Ci (35 m $\mu$ moles) of 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu, in 0.2 ml. On day 2, each animal was injected intraperitoneally with 2  $\mu$ Ci (39 m $\mu$ moles) of the same concentration of histidine-2-<sup>14</sup>C. Both solutions were in physiological saline.

**Results.** The lack of dietary vitamin B<sub>12</sub> affected both growth and methylmalonic acid excretion (Table I).

The mean body weight of animals in the +B<sub>12</sub> +Met diet group was greater than that of animals in the 3 groups that lacked adequate vitamin B<sub>12</sub> and/or methionine. Daily urinary methylmalonic acid excretion doubled in animals fed diets deficient in vitamin B<sub>12</sub>, regardless of the methionine status.

The <sup>14</sup>CO<sub>2</sub> excretion tracings (Fig. 1) revealed that the rate of <sup>14</sup>CO<sub>2</sub> production from histidine-2-<sup>14</sup>C was greatly reduced in animals fed the –B<sub>12</sub> –Met diet relative to those supplemented with vitamin B<sub>12</sub> and methionine. <sup>14</sup>CO<sub>2</sub> excretion tracings for 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu were similar except that the *T*<sub>max</sub> was delayed in the doubly deficient animals (Fig. 1).

A summary of the data obtained from individual animals is shown in Tables II and III. After injection of histidine-2-<sup>14</sup>C, the maximum rate of <sup>14</sup>CO<sub>2</sub> production and percent-

<sup>8</sup> Nuclear-Chicago Corp., Des Plaines, Ill.

<sup>9</sup> Cary Model 31, Applied Physics Corp. Monrovia, Calif.

<sup>10</sup> Electronik 15, Honeywell, Inc., Philadelphia, Pa.

TABLE I. The Effect of Vitamin B<sub>12</sub> and Methionine on Growth and Methylmalonic Acid Excretion in Rats.

Diet group	No. of rats	Basal diet supplements		% Total methionine	Body wt (g)	24-hr urinary methylmalonic acid ( $\mu$ moles/100 g of body wt)
		Vit B <sub>12</sub> (100 $\mu$ g/kg)	D,L-Met (3 g/kg)			
-B <sub>12</sub> -Met	4	-	-	0.2	316 $\pm$ 24 <sup>a</sup>	21.4 <sup>b</sup>
+B <sub>12</sub> -Met	4	+	-	0.2	308 $\pm$ 27	8.4 <sup>c</sup>
-B <sub>12</sub> +Met	4	-	+	0.5	319 $\pm$ 31	16.5 <sup>b</sup>
+B <sub>12</sub> +Met	4	+	+	0.5	348 $\pm$ 30	7.2 <sup>c</sup>

<sup>a</sup>  $\pm$  Standard error of the mean =  $\{[\Sigma X^2 - (\Sigma x)^2/n]/[n(n-1)]\}^{1/2}$ .

<sup>b,c</sup> Means with different superscripts are significantly different ( $p < .02$ ).

age of dose expired in 60 min by animals in the -B<sub>12</sub> -Met group was 1/10 of corresponding values for groups supplemented with vitamin B<sub>12</sub> and/or methionine. The  $T_{max}$  was not significantly changed by any of the dietary treatments.

In contrast, when 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu was injected, the maximum rate of <sup>14</sup>CO<sub>2</sub> production and percentage of dose expired in 60 min was unaffected by dietary treatment, but the  $T_{max}$  was delayed in animals lacking dietary vitamin B<sub>12</sub>. Methionine supplementation only slightly affected the  $T_{max}$ .

Histidine-2-<sup>14</sup>C and 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu were

injected in approximately equal amounts, yet the maximum rate of <sup>14</sup>CO<sub>2</sub> production and the percentage of dose expired in 60 min was 3 times higher after injection of the former than after injection of the latter, in all groups except the -B<sub>12</sub> -Met group where histidine catabolism was severely impaired.

*Discussion.* Elevated methylmalonic acid excretion has gained acceptance as a specific diagnostic of vitamin B<sub>12</sub> deficiency (19-22).

TABLE II. Pulmonary <sup>14</sup>CO<sub>2</sub> Excretion After Intraperitoneal Injection of Histidine-2-<sup>14</sup>C.

Diet group	$T_{max}$ (min)	Maximum rate ( $\mu$ Ci/min)	% Dose expired in 60 min
-B <sub>12</sub> -Met	26.4	$0.32 \times 10^{-3a}$	0.79 <sup>c</sup>
+B <sub>12</sub> -Met	29.2	$3.37 \times 10^{-3b}$	6.31 <sup>d</sup>
-B <sub>12</sub> +Met	39.3	$3.91 \times 10^{-3b}$	7.15 <sup>d</sup>
+B <sub>12</sub> +Met	29.4	$3.20 \times 10^{-3b}$	6.23 <sup>d</sup>

<sup>a,b,c,d</sup> Means for each column with different superscripts are significantly different ( $p < .01$ ).

TABLE III. Pulmonary <sup>14</sup>CO<sub>2</sub> Excretion After Intravenous Injection of <sup>14</sup>CH<sub>3</sub>-tetrahydrofolate.

Diet group	$T_{max}$ (min)	Maximum rate ( $\mu$ Ci/min)	% Dose expired in 60 min
-B <sub>12</sub> -Met	49.6 <sup>a</sup>	$1.08 \times 10^{-3c}$	2.12 <sup>d</sup>
+B <sub>12</sub> -Met	28.2 <sup>b</sup>	$0.89 \times 10^{-3}$	2.25
-B <sub>12</sub> +Met	41.1 <sup>a</sup>	$0.97 \times 10^{-3}$	1.90
+B <sub>12</sub> +Met	30.9 <sup>b</sup>	$1.01 \times 10^{-3}$	1.93

<sup>a,b</sup> Means with different letters are significantly different ( $p < .01$ ).

<sup>c,d</sup> No significant differences in mean values.





FIG. 1. Pulmonary <sup>14</sup>CO<sub>2</sub> production from L-histidine-2-<sup>14</sup>C or 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu in rats fed a diet either deficient or supplemented with vitamin B<sub>12</sub> and D,L-methionine. The  $T_{max}$  is indicated by a closed circle for each curve.

Using this criterion, animals in the —B<sub>12</sub> —Met and —B<sub>12</sub> +Met diet groups were definitely deficient in vitamin B<sub>12</sub>. The reduction in histidine-2-<sup>14</sup>C oxidation observed in the former group (Fig. 1 and Table II), despite 5 mg of folic acid/kg of diet, is indicative of secondary folic acid deficiency. We have also observed a large reduction in total folate levels in the livers of animals fed a similar diet (23).

The rate of oxidation of a <sup>14</sup>C-labelled compound such as histidine-2-<sup>14</sup>C or 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu to <sup>14</sup>CO<sub>2</sub> in the intact animal is a function of the rate of several biochemical steps. Not only is it dependent on the activity of the rate-limiting enzyme involved in the catabolism of the organic compound to CO<sub>2</sub>, but it is also dependent on the pool sizes of the injected compound and its products, the rate of transport of the compound into the tissues where oxidation occurs and on the rate of CO<sub>2</sub> production from bicarbonate. We can represent these first order, consecutive reactions as follows:



A is the isotopic organic compound injected,  $k_1$  is the rate constant for the sum of the metabolic processes involved in the uptake and oxidation of A, and  $k_2$  is the rate constant for the production of <sup>14</sup>CO<sub>2</sub> from <sup>14</sup>C bicarbonate. In our experiment, we have assumed that  $k_2$  is constant and greater than  $k_1$  in all groups. Therefore, changes in the rate-limiting step alters  $k_1$ .

$T_{\max}$ , which is independent of the specific activity of A, HCO<sub>3</sub><sup>-</sup>, and CO<sub>2</sub>, is related to the rate constants by the following equation:

$$T_{\max} = \frac{\ln(k_2/k_1)}{k_2 - k_1}. \quad (2)$$

If  $k_1 < k_2$  as we have assumed, then  $T_{\max}$  is inversely related to  $k_1$ .

A delay in  $T_{\max}$  has been reported by Fish *et al.* (24) for histidine-2-<sup>14</sup>C oxidation in folic acid-deficient humans. Our results in vitamin B<sub>12</sub>-deficient rats show no differences in  $T_{\max}$  for histidine-2-<sup>14</sup>C oxidation, with or without added dietary methionine, although

the  $T_{\max}$  for the —B<sub>12</sub> —Met group could not be accurately determined since the <sup>14</sup>CO<sub>2</sub> tracings are nearly flat (Fig. 1).

The maximal rate of <sup>14</sup>CO<sub>2</sub> production from histidine-2-<sup>14</sup>C and the percentage of dose excreted in 60 min are dependent on the pool size of histidine and its metabolites such as FIGlu and also on the rate of urinary excretion of FIGlu. These may be expected to be increased in the —B<sub>12</sub> —Met group due to a block in the formiminotransferase reaction. Our data give evidence that one or both of these are increased in the —B<sub>12</sub> —Met group since the maximal rate of <sup>14</sup>CO<sub>2</sub> production and the percentage of the dose excreted is reduced to 10% of the values in the groups supplemented with methionine and/or vitamin B<sub>12</sub> (Table II). Brown *et al.* (7) have reported that the imidazole-2-<sup>14</sup>C of histidine appears in urinary FIGlu in vitamin B<sub>12</sub> deficiency in the same amount as in the pulmonary <sup>14</sup>CO<sub>2</sub> in rats given methionine.

An interference with absorption or cellular transport of histidine by methionine has been proposed by Stahelin *et al.* to explain an observed reduction in histidine-2-<sup>14</sup>C catabolism. Such an interference is unlikely in our diets because the added methionine brought the total content to only 0.5%, an amount just satisfying the requirement for the rat.

The  $T_{\max}$  for the oxidation of 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu to <sup>14</sup>CO<sub>2</sub> was increased by vitamin B<sub>12</sub> deficiency (Table III). From Eq. (2), the rate constant  $k_1$  must have decreased. Such a decrease was probably due to an impairment in the methyltransferase reaction. *In vitro* evidence shows a reduction in the activity of this enzyme in vitamin B<sub>12</sub>-deficient rats (26).

In contrast with the results obtained for histidine-2-<sup>14</sup>C (Table II), the maximal rate of <sup>14</sup>CO<sub>2</sub> production from 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu and the percentage dose excreted in 60 min was not significantly altered by any dietary treatment. This contradicts what would be expected in vitamin B<sub>12</sub> deficiency if current concepts are correct. According to the "methyl trap" hypothesis the 5-CH<sub>3</sub>-H<sub>4</sub>PteGlu pool size should be increased in vitamin B<sub>12</sub> deficiency resulting in a decrease in specific activity of injected 5-<sup>14</sup>CH<sub>3</sub>-

H<sub>4</sub>PteGlu, and consequently in the amount and rate of <sup>14</sup>CO<sub>2</sub> produced. Since the labeled methyl group is transferred to homocysteine before oxidation, it would be expected that methionine supplementation would also affect the rate of production of <sup>14</sup>CO<sub>2</sub> from 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu. No such effect was observed (Table III). Our results for 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu oxidation are not easily explained by present hypotheses unless a "tight" regulatory mechanism of 5-CH<sub>3</sub>-H<sub>4</sub>PteGlu metabolism is assumed.

Significantly, the methyl group of 5-<sup>14</sup>CH<sub>3</sub>-H<sub>4</sub>PteGlu was oxidized at an equal rate in vitamin B<sub>12</sub> deficiency with, or without, added methionine, while the imidazole-2-<sup>14</sup>C of histidine was not. It is difficult to agree that there is a "methyl trap" in the simple terms of an accumulation of 5-CH<sub>3</sub>-H<sub>4</sub>PteGlu in tissues and a consequent reduction of H<sub>4</sub>PteGlu for acceptance of the formimino group. The explanation must be more complicated and perhaps be related to the function of the other forms of folate, the tri- and polyglutamates, or a transport phenomenon which is dependent on vitamin B<sub>12</sub> and/or methionine.

*Summary.* When rats were fed a diet deficient in vitamin B<sub>12</sub> and limiting in methionine, the <sup>14</sup>CO<sub>2</sub> production from L-histidine-2-<sup>14</sup>C was reduced in comparison with rats fed diets supplemented with vitamin B<sub>12</sub> and/or methionine. In contrast, the production of <sup>14</sup>CO<sub>2</sub> from 5-<sup>14</sup>CH<sub>3</sub>-tetrahydrofolic acid was not altered by vitamin B<sub>12</sub> deficiency or the level of dietary methionine. The T<sub>max</sub> for the oxidation of 5-<sup>14</sup>CH<sub>3</sub>-tetrahydrofolic acid to <sup>14</sup>CO<sub>2</sub> was delayed in vitamin B<sub>12</sub> deficiency in comparison with normals, indicating that either an enzymatic reaction or transport into tissues becomes rate-limiting in the deficient state.

1. Beck, W. S., *Medicine (Baltimore)* **43**, 715 (1964).
2. Silverman, M., Gardiner, R. C., and Bakerman, H. A., *J. Biol. Chem.* **194**, 815 (1952).
3. Rabinowitz, J. C., and Tabor, H., *J. Biol. Chem.* **233**, 252 (1958).
4. Silverman, M., and Pitney, A. J., *J. Biol. Chem.* **233**, 1179 (1958).
5. Fox, M. R. S., and Ludwig, W. J., *Proc. Soc. Exp. Biol. Med.* **108**, 703 (1961).
6. Zalusky, R., and Herbert, V., *J. Clin. Invest.* **40**, 1091 (1961).
7. Brown, D. D., Silva, O. L., Gardiner, R. C., and Silverman, M., *J. Biol. Chem.* **235**, 2058 (1960).
8. Herbert, V., and Sullivan, L. W., *Proc. Soc. Exp. Biol. Med.* **112**, 304 (1963).
9. Katzen, H. M., and Buchanan, J. M., *J. Biol. Chem.* **240**, 825 (1965).
10. Keresztesy, J. C., and Donaldson, K. O., *Biochem. Biophys. Res. Commun.* **5**, 286 (1961).
11. Noronha, J. M., and Silverman, M., "Vitamin B<sub>12</sub> and Intrinsic Factor, 2nd European Symposium, Hamburg," p. 728. Enke, Stuttgart, West Germany (1962).
12. Herbert, V., and Zalusky, R., *J. Clin. Invest.* **41**, 1263 (1962).
13. Buchanan, J. M., Elford, H. L., Loughlin, R. E., McDougall, B. M., and Rosenthal, S., *Ann. N. Y. Acad. Sci.* **112**, 756 (1964).
14. Chanarin, I., and McLean, A., *Clin. Sci.* **32**, 57 (1967).
15. Williams, M. A., Chu, L.-C., McIntosh, D. J., and Hincenbergs, I., *J. Nutr.* **94**, 377 (1968).
16. Giorgio, A. J., and Plaut, G. W. E., *J. Lab. Clin. Med.* **66**, 667 (1965).
17. Tolbert, B. M., Kirk, M., and Baker, E. M., *Amer. J. Physiol.* **185**, 269 (1956).
18. Jeffay, H., and Alvarez, J., *Anal. Chem.* **33**, 612 (1961).
19. Cox, E. V., and White, A. M., *Lancet* **2**, 853 (1962).
20. Barness, L. A., Young, D., Mellman, W. J., Kahn, S. B., and Williams, W. J., *N. Engl. J. Med.* **268**, 144 (1963).
21. Barness, L. A., Young, D. G., and Nocho, R., *Science* **140**, 76 (1963).
22. Armstrong, B. K., *Brit. J. Nutr.* **21**, 309 (1967).
23. Gawthorne, J. M., and Stokstad, E. L. R., *Fed. Proc., Fed. Amer. Soc. Exp. Biol.* **28**, 628 (1969).
24. Fish, M. B., Pollycove, M., and Feichtmeir, T. V., *Blood* **21**, 447 (1963).
25. Stahelin, H. B., Winchell, H. S., and Kusubov, N., *Blood*, **35**, 86 (1970).
26. Kutzbach, C., Galloway, E., and Stokstad, E. L. R., *Proc. Soc. Exp. Biol. Med.* **124**, 801 (1967).